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Summary
 Background Approximately 60–80% of metastatic prostate cancer patients suffer from pain 
caused by bone metastases. Bone metastases have a negative impact on patient 
performance status.
 Aim The aim of study was to compare the efﬁ cacy of treatment with strontium 89 or sa-
marium 153 in monotherapy vs. radioisotope treatment combined with external 
beam radiotherapy (EBRT) in prostate cancer patients with bone metastases.
 Materials/Methods We retrospectively analyzed one hundred (n=100) metastatic prostate cancer 
patients aged between 53 and 84 years, who we divided into four treatment 
groups: 30 pts received Sr-89 monotherapy; 30 patients received Sm-153 mono-
therapy; 20 pts received Sr-89 combined with EBRT; and 20 pts received Sm-153 
combined with EBRT. Follow-up was 4 months. All patients prior to therapy had 
their bone metastases conﬁ rmed by bone scan examination. Pathologic fractures 
were excluded and the nature of metastases (osteoblastic/mixed) was evaluated 
with X-ray ﬁ lms and/or CT and/or MRI. Sr-89 therapy consisted of a standard 
dose of 150MBq, while Sm-153 was administered proportionally to body weight 
(37MBq/kg). In combined treatment groups EBRT was given to the dominant 
metastatic site with 8Gy in one fraction or 20Gy in ﬁ ve daily fractions. Treatment 
efﬁ cacy was determined by change in pain intensity evaluated according to visu-
al analogue scale (VAS), changes in Karnofsky performance status (KPS) and in 
the use of analgesics.
 Results Complete pain relief (VAS<3) was observed in 33% and 40% of patients in Sr-89 
and Sm-153 monotherapy groups and in 50% and 60% of patients treated with 
Sr-89 and Sm-153 therapy combined with EBRT, respectively. Unsatisfactory re-
sponse to treatment (VAS>5) was noted in 20% of patients in both monothera-
py groups and in 10% and 15% of patients in Sm-153 and Sr-89 combined with 
EBRT, respectively. Decrease in pain intensity and in the use of analgesics as well 
as improvement in performance status were statistically signiﬁ cant for combined 
therapy vs. monotherapy (p<0.05). Treatment was well tolerated, with 3 patients 
suffering from severe pancytopenia and 22 patients with mild leucopenia and/or 
thrombocytopenia.
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BACKGROUND
Approximately 60–80% of metastatic prostate can-
cer patients suffer from pain caused by bone me-
tastases. The most common sites of bone metastas-
es in prostate cancer are vertebral column, ribs, 
pelvic bones and cranium [1,2]. The decision of 
which therapeutic option to use in the treatment 
of bone metastases (surgery, external beam radi-
otherapy (EBRT), radioisotopes or bisphospho-
nates) depends on the stage of disease, anatomi-
cal site and type of bone remodelling. After years 
of studies it has been postulated that bone metas-
tases originating from different primary organs 
differ signiﬁ cantly in their inﬂ uence on function 
of osteoclasts and osteoblasts. Neoplastic cells 
may directly or indirectly (e.g. by stimulation of 
the immunological system) stimulate via chem-
ical mediators (PTH-rP, IL-6, TNF, TGF) osteo-
clasts or osteoblasts or only modify their activity 
[3,4]. Such pathologically enhanced activity of 
osteoclasts results in intensiﬁ cation of osteolyt-
ic processes accompanied by tendency to hyper-
calcaemia. On the other hand, increased stimu-
lation of osteoblasts results in overproduction of 
bone matrix and hypercalciﬁ cation. However, in 
the majority of patients both above-mentioned 
processes take place without a distinct imbalance 
between them – such metastases are classiﬁ ed as 
mixed [2,4]. Bone metastases are best imaged 
and diagnosed with a bone scan, which beside its 
conﬁ rmatory diagnostic value also gives informa-
tion on the level of dissemination of the disease 
and localization of lesions (it is possible to visu-
alize lesions as small as 1.5–2mm in diameter). 
Examination with X-ray ﬁ lm remains a valuable 
supplement to diagnosis obtained solely by bone 
scan – it can provide data which are not possible 
to obtain from a bone scan, such as presence of 
pathologic fracture or differentiation between os-
teolytic and osteosclerotic lesions. However, the 
sensitivity of X-ray examination to detect bone 
metastases is about four to even ﬁ ve times lower 
than that of a bone scan. Computed tomography 
(CT) and magnetic resonance imaging (MRI) 
are mainly reserved for cases in which the results 
of bone scan and X-ray examinations are indeci-
sive and the result of the examination determines 
the type of therapy to be administered. Recently 
also positron emission tomography (PET) is be-
ing incorporated into more and more cases of di-
agnosis of bone metastases in patients with pros-
tate cancer [1–4].
Patients who are qualiﬁ ed for radioisotope ther-
apy typically have multiple osteoblastic lesions; 
however, partial responses are also reported in 
the subgroup of patients with small osteolytic le-
sions (large and advanced osteolytic metastas-
es usually do not respond to radioisotope ther-
apy)[5–7].
AIM OF STUDY
The aim of the study was to compare the efﬁ cacy 
of treatment with strontium 89 or samarium 153 
in monotherapy vs. radioisotope treatment com-
bined with external beam radiotherapy (EBRT) in 
prostate cancer patients with bone metastases.
MATERIALS AND METHODS
We retrospectively analyzed one hundred (n=100) 
metastatic prostate cancer patients aged between 
53 and 84 years. All patients prior to therapy had 
their bone metastases conﬁ rmed by bone scan ex-
amination. Pathologic fractures were excluded 
and the nature of metastases (osteoblastic /mixed) 
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was evaluated with X-ray ﬁ lms and/or CT and/or 
MR; 75 patients had typical osteoblastic metas-
tases and 25 patients had mixed type of metas-
tases. The most common locations of metastases 
were as follows: the lumbo-sacral part of the ver-
tebral column was affected in 70% of patients, 
pelvic bones in 60%, and ribs in 50% of patients. 
The majority of patients suffered from general-
ized pain from multiple (more than 3) pain sites. 
Almost all patients were treated before entering 
the study with bisphosphonates and analgesics 
with disappointing results. Patients were divided 
into four treatment groups: 30 pts received Sr-89 
monotherapy; 30 patients received Sm-153 mon-
otherapy; 20 pts received Sr-89 combined with 
EBRT; and 20 pts received Sm-153 combined 
with EBRT. Strontium 89 therapy consisted of a 
standard dose of 150MBq, while Samarium 153 
was administered proportionally to body weight 
(37MBq/kg). In combined treatment groups 
EBRT was given to the dominant metastatic pain 
site (mostly in the vertebral column and pelvic 
bones) with 8Gy in one fraction or 20Gy in ﬁ ve 
daily fractions. External beam radiotherapy was 
typically administered 2 to 4 weeks after radio-
isotope treatment. Treatment efﬁ cacy was de-
termined by change in pain intensity evaluated 
according to the visual analogue scale (VAS), 
changes in Karnofsky performance status (KPS) 
and in the use of analgesics. The VAS scale is a 
10-point scale where 0 stands for no pain and 10 
means terrible, unbearable pain. Karnofsky per-
formance status scale has 100 points, where death 
is represented by 0 points and fully active well-
being is equal to 100 points. As complete thera-
peutic effect in pain treatment we assumed de-
crease in VAS scale below 3 points; partial effect 
was between 3 and 5 points; and unsatisfactory 
effect was deﬁ ned as lack of VAS scale decrease 
below 6 points.
In statistical analysis of data with normal Gaussian 
distribution the evaluation of agreement was per-
formed with Shapiro-Wilk test, while testing for 
difference was done with Student’s t-test or vari-
ance analysis with repeated measurements with 
Bonferoni’s test. For data with non-Gaussian distri-
bution testing for differences was performed with 
Mann-Whitney and Freedman test and for mul-
tiple comparisons with Dunn test. Correlations 
were tested with Pearson’s correlation coefﬁ -
cient for data with normal distribution and with 
Spearman’s correlation coefﬁ cient in other cas-
es. Hypotheses were tested at the level of signif-
icance a=0.05.
RESULTS
Prior to therapy median pain intensity recorded 
with VAS scale was 7 (very strong pain), ranging 
from 6 to 10, while performance status evaluat-
ed with Karnofsky scale varied between 40 and 
80 with median score of 50. These numbers were 
similar across subgroups of patients treated with 
Sr-89 and Sm-153 respectively. Differences were 
not statistically signiﬁ cant (p>0.05). Gradual de-
crease in pain intensity was observed typically as 
early as at 8–14 days after radioisotope therapy. 
After 2 months VAS score for the whole group 
had decreased in a statistically signiﬁ cant fashion 
(p<0.05) and median score of VAS was 3 (low in-
tensity periodical pain) with a range of 0 to 8.
A detailed description of pain treatment is giv-
en in Table 1.
Statistical analysis did not show statistically sig-
niﬁ cant differences between efﬁ cacy of mono-
therapy with Sr-89 and Sm-153 (p>0.05); howev-
er, a trend has emerged toward higher efﬁ cacy 
of samarium in comparison with strontium in pa-
tients with mixed type of metastases. It has been 
proved that combined therapy consisting of radi-
oisotope and external beam radiotherapy statisti-
cally signiﬁ cantly increased efﬁ cacy of treatment 
(p<0.05). For all groups a signiﬁ cant improve-
ment was noted in terms of activity according to 
the Karnofsky scale – the score increased from 
50 to 80; observed differences were statistically 
signiﬁ cant (p<0.05). The amount of analgesics 
Response
Treatment
Sr-89 Sm-153 Sr-89 + EBRT Sm-153 + EBRT
Complete  33% (10)  40% (12)  50% (10)  60% (12)
Partial  47% (14)  40% (12)  35% (7)  30% (6)
Unsatisfactory  20% (6)  20% (6)  15% (3)  10% (2)
Table 1. Effi  cacy of pain treatment.
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used decreased by a mean value of 50% com-
pared to the number of analgesics used prior to 
treatment with radioisotope and EBRT. Efﬁ cacy 
of treatment in terms of changes of VAS, KPS and 
use of analgesics is shown in Table 2.
After 16 weeks analgesic response remained sat-
isfactory in 80% of patients. In terms of adverse 
effects of therapy there were 3 cases of severe 
pancytopenia reported (2 cases after Sr-89 and 
1 case in the Sm-153 group) and 22 cases of sig-
niﬁ cant, albeit short-term and not necessitating 
any further treatment, decrease in leukocyte and 
platelets count (11 after Sr-89 and 11 after Sm-
153). Overall, myelotoxicity was more frequently 
observed in the combined therapy groups (30% 
vs.22%), but there were no signiﬁ cant differenc-
es in clinical course of treatment related to that 
difference. Hypercalcaemia was noted in 5 pa-
tients, and was successfully treated with bisphos-
phonate therapy.
Studies on correlation of treatment efﬁ cacy and 
levels of PSA did not show statistical signiﬁ cance; 
however, there was a trend toward lower efﬁ cacy 
of treatment in patients with elevated levels of al-
kaline phosphatase.
DISCUSSION
Radioisotope treatment of bone metastases re-
mains a palliative approach, with the main aim 
of treatment being alleviation of pain and pre-
vention of progression of metastatic lesions and 
pathologic fractures. Loco-regional external beam 
radiotherapy is undoubtedly a more efﬁ cient 
method of pain treatment than radioisotope ther-
apy. However, in the case of multiple lesions it is 
impractical or even impossible to cover all pain 
sites with treatment and in such cases radioiso-
topes remain the treatment of choice [7–9]. As 
previously mentioned, the optimal patients re-
ferred for radioisotope therapy are those with 
multiple, osteoblastic or mixed type metastas-
es to bones, under condition that radioisotope 
will be selectively accumulated in the lesion. 
Accumulation of radioisotope results in selec-
tive irradiation of metastatically transformed 
bone with minimal risk of toxicity to surround-
ing normal tissues. Killing even only a fraction 
of neoplastic cells in a metastatic lesion in bone 
results in a decrease in release of inﬂ ammatory 
and pain mediators and at the same time by low-
ering the mass of metastasis diminishes mechan-
ical irritation of pain receptors [5,6,10]. When 
analyzing the results of treatment with radioiso-
topes, attention must be paid to the signiﬁ cant 
differences in their characteristics. The mech-
anism of uptake of studied radioisotopes var-
ies distinctly, which may have important conse-
quences in terms of overall efﬁ cacy of treatment. 
Strontium 89 is a calcium analogue and as such 
will be taken up and incorporated into collagen 
ﬁ bres in all sites of enhanced bone transforma-
tion, which is typical for osteoblastic metastases 
to bones. Thanks to the long biological half-life 
of Sr-89 of 50.5 days, doses may be proportional-
ly low, because for such a long period after incor-
poration into the osteoblastic lesion the radioiso-
tope will exert its therapeutic action. Samarium 
153 is administered as a chelated tetraphospho-
nian compound (lexidronian), which implies 
its high speciﬁ city and selectiveness of accumu-
lation in places of bone transformation (afﬁ nity 
to hydroxyapatyte) induced by presence of neo-
plastic cells. Half-life of Sm-153 is 1.9 days, which 
determines the necessity to administer high ac-
tiveness (dose); however, on the other hand it 
makes such treatment similar in fashion to the 
classic EBRT approach (high dose in short overall 
Treatment
option
Change in pain intensity;
VAS scale (0–10)
Change in performance status; 
KPS (0–100)
Decrease in the use
of analgesics
Sr-89 –3range (–8 to +2)
+20
(–20 to +40) 40%
Sm-153 –3(–7 to +1)
+30
(–20 to +40) 45%
Sr-89 + EBRT –5(–7 to +2)
+30
(–20 to +40) 55%
Sm-153 + EBRT –5(–8 to +2)
+30
(–20 to +40) 60%
Table 2. Effi  cacy of treatment – changes of VAS, KPS and use of analgesics (median value and range of scores).
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treatment time). With a high dose administered 
the efﬁ cacy of the therapy will be sufﬁ cient even 
if the radioisotope binds to hydroxyapatyte for 
only a short time [2,6,11,12]. The mechanisms 
of action of samarium and strontium described 
in previous paragraphs explain the similar efﬁ -
cacy of both radioisotopes in cases of osteoblas-
tic bone metastases (in monotherapy reported 
efﬁ cacy of 75–80%) [6,11–15]. In the case of sa-
marium treatment, solid osteoblastic lesions with 
high proportion of hydroxyapatyte sufﬁ ciently 
bind this compound, while in the case of stron-
tium it is the high activity of osteoblasts that en-
ables such a large amount of radioisotope to be 
incorporated into pathologically transformed 
bone matrix. In treatment of mixed metastases, 
efﬁ cacy of treatment decreases proportionally 
to increase of osteolytic component and size of 
lesion. In such patients the treatment of choice 
should be Sm-153. The reason for this recommen-
dation lies in the large disproportion of activity 
of osteoclasts and osteoblasts within ostolytic le-
sions – the possibility of fast incorporation and 
longer “sheltering” for strontium in the metastat-
ic lesion is then small – which will result in rel-
atively low accumulated dose of irradiation and 
obviously less effective pain treatment. Slightly 
higher efﬁ cacy of samarium in this setting re-
sults from less speciﬁ c mechanism of binding 
to hydroxyapatyte – a high dose even if bound 
more “loosely” and for a short time will inevita-
bly give at least a partial therapeutic effect. Our 
observations suggest slightly higher and often 
delayed myelotoxicity for Sr-89, especially in the 
younger subset of patients. However, what is wide-
ly conﬁ rmed in literature data, the percentage 
of early haematological complications is similar 
for both radioisotopes, accounting for approxi-
mately 25% of cases. The risk of such complica-
tions increases proportionally to not only eve-
ry administered dose of radioisotope but also is 
a result of prior or concurrent treatment with 
other anticancer modalities such as radiothera-
py, chemotherapy, hormonotherapy or sympto-
matic pain treatment, etc. [5,6,16,17]. Analgesic 
effect of Sm-153 in our study as well as in litera-
ture data appears a little earlier than after Sr-89 
treatment, but according to many authors is also 
shorter and therefore requires more frequently 
repeated treatment [5,6,11,12]. Combining radi-
oisotope therapy with pharmacotherapy with bi-
sphosphonates requires detailed knowledge on 
mechanisms of action of both treatments. Sr-89 
as a calcium analogue competes with ionized cal-
cium circulating in blood to be taken up within 
the bone. Therefore concurrent treatment with 
calcium may lower the efﬁ cacy of this radioiso-
tope. As for bisphosphonates, no interaction has 
been reported with Sr-89 treatment when admin-
istered concurrently (different points of uptake in 
the bone). Moreover, administering bisphospho-
nates immediately after injection of radioisotopes 
practically precludes the risk of hypercalcaemia, 
which is quite common after Sr-89 therapy, with 
incidence reported to be 15%. The analgesic ef-
fect of such treatment may be even doubled. It is 
a similar situation for Sm-153 therapy, although 
in that case it is indicated to withhold therapy 
with bisphosphonates at least 2 to 4 weeks prior 
to planned radioisotope treatment (possibility of 
competitive antagonism of uptake between tetra-
phosphonate Sm-153 composite and bisphospho-
nate). Administering bisphosphonate on the third 
day after radioisotope therapy not only does not 
decrease the efﬁ cacy of treatment but also inhib-
its the development of hypercalcaemia and may 
enhance the analgesic effect [18]. Similarly, posi-
tive results may be obtained with combining radi-
oisotope therapy with external beam radiothera-
py or chemotherapy. Unfortunately, each of these 
combinations is related to an increase in proba-
bility of side effects (6,7,9,12,17). It can be con-
cluded that efﬁ cacy of radioisotope treatment is 
not only dependent on type of cancer and dose 
and type of radioisotope used, but is a combina-
tion of some other factors such as number, size, 
location and type of bone metastases, presence 
of fractures, presence of neuropathic pain as well 
as scheme of therapy (monotherapy or polyther-
apy) [6,14,19,20].
CONCLUSIONS
1. Combining Sr-89 and Sm-153 radioisotope 
therapy with local radiotherapy signiﬁ cantly in-
creases efﬁ cacy of treatment, decreases use of 
analgesics and risk of pathologic fractures and 
statistically signiﬁ cantly increases the quality of 
life.
2. Serious complications after radioisotope ther-
apy (also when combined with radiotherapy) 
are rather infrequent and in most cases result 
from improper referral for such treatment.
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